Analyzing non-coding RNA in patients with acute ischemic stroke
Official title: Clinical Significance of Circulating Non-coding RNA in Acute Ischemic Stroke (AISRNA)
Run by Nanjing First Hospital, Nanjing Medical University · NCT04175691 · Data updated 2026-11-12
This study is trying to see if certain types of non-coding RNA in the blood can help doctors better detect and understand the outcomes of patients who have had an acute ischemic stroke.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 500 (estimated) |
| Sponsor | Nanjing First Hospital, Nanjing Medical University Academic / other |
| Locations | 1 site (Nanjing, Jiangsu) |
| Status | Recruiting |
| Started | November 24, 2019 |
| Main results expected | December 31, 2026 |
| Study ends | December 31, 2026 |
| Registry record updated | April 15, 2026 |
| Trial ID | NCT04175691 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are adults aged 18 years or older who have been diagnosed with acute ischemic stroke within 72 hours of symptom onset.
✕Probably not a fit
Patients with a history of hemorrhagic infarction, chronic kidney or liver diseases, peripheral arterial occlusive disease, active malignant disease, or inflammatory or infectious diseases may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study investigates the expression patterns of circular RNA (circRNA), micro-RNA (miRNA), and long non-coding RNA (lncRNA) in patients diagnosed with acute ischemic stroke compared to healthy controls. Using next-generation sequencing, the study aims to identify distinctive expression patterns of these non-coding RNAs that may serve as biomarkers for the detection and prognosis of acute ischemic stroke. The findings will be validated through quantitative real-time polymerase chain reaction (qRT-PCR) and a diagnostic model will be developed using logistic regression to assess the clinical significance of these biomarkers.
Why it matters
Potential benefit: If successful, this study could lead to the development of novel biomarkers for the early detection and prognosis of acute ischemic stroke.
How similar studies have gone: While the exploration of non-coding RNAs in stroke is a growing field, this specific approach using next-generation sequencing for acute ischemic stroke biomarkers is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Aged 18 years or older * Confirmed acute ischemic stroke by a diffusion-weighted imaging-position lesion on magnetic resonance imaging (MRI) and a new lesion on a brain computed tomography (CT) scan * Within 72 hours of symptom onset * Good performance status * Signed an approved informed consents Exclusion Criteria: -a history of hemorrhagic infarction, chronic kidney/liver diseases, peripheral arterial occlusive disease, active malignant disease, and inflammatory or infectious diseases
Where it's running
-
Nanjing First Hospital, Nanjing Medical University
Nanjing, Jiangsu, China Recruiting
Study contacts
- Study coordinator: Junshan Zhou, M.D.
- Email: zhjsh333@126.com
- Phone: +8602587726218
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Best Care for Acute Stroke in General Wards
A nurse-led program called BEST CARE ICTUS_HC is tested in hospitals without Stroke Units to see if it reduces stroke complications and helps recovery after an acute ischemic or hemorrhagic stroke.
-
Continuous Dual Aspiration with the Zoom System for Acute Ischemic Stroke
This trial will try using the Zoom aspiration system with a continuous dual aspiration technique to remove clots in adults with acute ischemic stroke.
-
Dimephosphon® for recovery after acute ischemic stroke.
This trial will test whether Dimephosphon® given 24–72 hours after stroke onset helps adults with moderate acute ischemic stroke recover better than a placebo.
-
Treatment for Acute Ischemic Stroke using DM199
This study is testing if a new treatment called DM199 can help people with moderate acute ischemic stroke recover better when given soon after their symptoms start.
-
Registry connecting stroke survivors with research opportunities
This study connects stroke survivors with research opportunities to help find new treatments that can improve their recovery.
-
AI-based tools to help diagnose, treat and predict stroke outcomes across multiple hospitals
This study tests AI-powered tools on real-world stroke patients to see if they can improve pre-hospital triage, diagnosis, and outcome prediction while data stay securely within each hospital.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.